{"filings":[{"id":1196716,"accession_number":"0001193125-26-277639","cik":1593899,"company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","form_type":"8-K","filed_at":"2026-06-22T20:53:52+00:00","items":["5.07"],"status":"ready","headline":"Atea stockholders reelect all three Class III directors; KPMG ratified; say-on-pay passes","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Jerome Adams, Howard Berman, Barbara Duncan elected as Class III directors (for votes: 28.8M, 44.5M, 43.7M).","Ratification of KPMG as auditor for FY2026: 58.9M for, 0.78M against, 65.5K abstain.","Advisory approval of exec compensation: 47.5M for, 3.0M against, 643.6K abstain; broker non-vote 8.7M.","Approximately 74.65% of outstanding shares represented at the meeting (59.7M shares)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":376127383.4285714,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":40724,"accession_number":"0001193125-26-219507","cik":1593899,"company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","form_type":"8-K","filed_at":"2026-05-12T20:17:39+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atea Q1 net loss $45.4M ($0.57/shr); HCV Phase 3 topline mid-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $45.4M vs $34.3M YoY; R&D spend rose to $41.1M on HCV Phase 3 and HEV preclinical.","Cash, equivalents & marketable securities $256.0M at March 31, 2026, down from $301.8M at Dec 2025.","C-BEYOND HCV Phase 3 (North America) enrollment completed; topline results expected mid-2026.","C-FORWARD HCV Phase 3 (ex-North America) enrollment on track to complete mid-2026; topline around year-end 2026.","HEV program: AT-587 selected as lead; in vitro data 30-150x more potent than sofosbuvir/ribavirin; Phase 1 initiation planned mid-2026."],"consensus_eps_estimate":-0.6018,"consensus_eps_actual":-0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":376127383.4285714,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105974,"accession_number":"0001193125-26-093961","cik":1593899,"company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atea reports Q4 net loss $44.9M, cash $301.8M; HCV Phase 3 topline mid-2026; HEV program mid-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $44.9M in Q4 2025 (EPS -$0.57) vs $33.5M loss in Q4 2024; full-year net loss $158.3M.","Cash and investments $301.8M at Dec 31, 2025, down from $454.7M a year ago.","R&D expense $47.8M in Q4, up from $25.7M YoY, driven by HCV Phase 3 spend including milestone to Merck.","Global Phase 3 HCV program: C-BEYOND (enrolled >880) topline mid-2026; C-FORWARD enrollment complete mid-2026, topline year-end 2026.","Expanded antiviral pipeline: HEV program with AT-587 expected to enter clinic mid-2026; presented in vitro data at CROI 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":376127383.4285714,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105973,"accession_number":"0001193125-26-007081","cik":1593899,"company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atea ends 2025 with $301.8M cash; Phase 3 HCV data due mid-2026; HEV program advancing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and investments $301.8M at Dec 31, 2025; cash runway expected through 2027.","Phase 3 HCV C-BEYOND topline results mid-2026; C-FORWARD results year-end 2026.","HEV Phase 1 study for AT-587 planned mid-2026; preclinical shows potent nanomolar anti-HEV activity.","Market survey of 153 top DAA prescribers supports need for new HCV regimen; global HCV market ~$3B net sales annually.","Atea will evaluate strategic transactions and global commercialization options to maximize reach."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":376127383.4285714,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122249,"accession_number":"0001193125-25-277627","cik":1593899,"company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atea Q3 net loss $42.0M ($0.53/share); HCV Phase 3 C-BEYOND fully enrolled by end-2025; HEV program launched","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $42.0M ($0.53 diluted EPS) vs $31.2M ($0.37) in Q3 2024; R&D expenses rose to $38.3M.","Cash, equivalents and marketable securities $329.3M at Sep 30, 2025, down from $454.7M at Dec 31, 2024.","HCV Phase 3 C-BEYOND (US/Canada) enrollment on track for completion by end 2025; topline mid-2026.","New HEV development program with two lead candidates AT-587 and AT-2490; IND-enabling studies ongoing.","Completed $25M stock repurchase program: 7,673,793 shares at avg $3.26; shares outstanding 78,126,796."],"consensus_eps_estimate":-0.4488,"consensus_eps_actual":-1.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":376127383.4285714,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138961,"accession_number":"0001193125-25-175433","cik":1593899,"company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atea Q2 net loss $37.2M ($0.44/shr); cash $379.7M; repurchases shares; strategic review ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $37.2M ($0.44 diluted EPS) vs $40.5M loss in Q2 2024; R&D expense $32.3M, down $2.4M YoY.","Cash, equivalents and marketable securities $379.7M at June 30, 2025, down from $454.7M at Dec 31, 2024.","Board authorized up to $25M share repurchase; 4.6M shares bought at avg $3.01 through June 30.","Engaged Evercore to evaluate strategic alternatives including partnerships, M&A, or sale of assets.","Global Phase 3 HCV program (C-BEYOND, C-FORWARD) enrolling on track; 98% SVR12 in Phase 2 per-protocol population."],"consensus_eps_estimate":-0.4233,"consensus_eps_actual":-0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":376127383.4285714,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156444,"accession_number":"0001193125-25-143750","cik":1593899,"company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Atea shareholders elect three Class II directors, ratify KPMG, approve executive compensation","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Bruno Lucidi, Polly Murphy, and Bruce Polsky elected as Class II directors to 2028 term.","Ratification of KPMG as independent auditor for FY2025 approved with 73.8M votes for.","Advisory (non-binding) approval of named executive officer compensation received 46.5M votes for.","Approximately 87.6% of outstanding shares represented at June 20, 2025 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":376127383.4285714,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156443,"accession_number":"0001193125-25-117809","cik":1593899,"company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atea Pharma Q1 net loss narrows to $34.3M; cash $425M; Phase 3 HCV trial enrolling","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $34.3M ($0.40/share) vs $63.2M ($0.75) in Q1 2024; R&D expense down 49% to $29.6M.","Cash, equivalents and marketable securities $425.4M at March 31, down from $454.7M at Dec 31.","Phase 3 C-BEYOND HCV trial enrolling; second Phase 3 C-FORWARD expected mid-2025.","Strategic alternatives review with Evercore ongoing; workforce reduced ~25% to save ~$15M through 2027.","Board authorized $25M share repurchase; Arthur Kirsch and Howard Berman appointed to board."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":376127383.4285714,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156442,"accession_number":"0001193125-25-083523","cik":1593899,"company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","form_type":"8-K","filed_at":"2025-04-17T23:59:59+00:00","items":["1.01","2.02","5.02","7.01","9.01"],"status":"ready","headline":"Atea appoints Howard Berman to board, authorizes $25M buyback after activist settlement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Howard H. Berman (Coya Therapeutics founder) appointed as Class III director effective after 2025 annual meeting; will serve as observer until then.","Agreement with activist investors Bradley Radoff and Michael Torok: slate withdrawn, standstill and voting commitments through mid-2026.","Franklin Berger will retire from board after his Class I term expires at 2027 annual meeting.","Board authorized up to $25M share repurchase program; strategic alternatives review with Evercore ongoing.","Preliminary cash, cash equivalents and marketable securities as of March 31, 2025: $425.4 million."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":376127383.4285714,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156441,"accession_number":"0001193125-25-069932","cik":1593899,"company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Atea announces withdrawal of director nomination by Driver Opportunity Partners","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Driver Opportunity Partners withdrew its intent to nominate J. Abbott R. Cooper for board election at the 2025 Annual Meeting.","As a result, Cooper will not stand for election at the meeting.","Atea received the withdrawal notice on March 31, 2025.","Action removes a potential proxy contest ahead of the annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":376127383.4285714,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174879,"accession_number":"0001193125-25-060794","cik":1593899,"company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Atea Pharmaceuticals receives director nominations from two stockholders for 2025 Annual Meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bradley L. Radoff nominates Howard H. Berman, James P. Flynn, and Michael Torok.","Driver Opportunity Partners III LP nominates J. Abbott R. Cooper for election.","Nominating Committee will evaluate candidates; formal recommendation in proxy statement.","No shareholder action required now; 2025 Annual Meeting date not yet scheduled.","Evercore and Latham & Watkins retained as financial and legal advisors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":376127383.4285714,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174878,"accession_number":"0001193125-25-048426","cik":1593899,"company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atea reports Q4/FY2024 results; cash at $454.7M; HCV Phase 3 starts April 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss per share Q4 2024 improved to ($0.40) from ($0.47); full year net loss per share ($2.00) vs ($1.63).","Cash, cash equivalents and marketable securities $454.7M at Dec 31, 2024 vs $578.1M year earlier.","Successful End-of-Phase 2 FDA meeting for HCV regimen bemnifosbuvir/ruzasvir; Phase 3 enrollment expected April 2025.","Reduced workforce by 25% in Q1 2025 to achieve ~$15M in cost savings through 2027.","Engaged Evercore for strategic partnerships for HCV Phase 3 program; appointed Arthur S. Kirsch to board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":376127383.4285714,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174877,"accession_number":"0001193125-25-032826","cik":1593899,"company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Atea Pharmaceuticals appoints Arthur Kirsch to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Arthur Kirsch, age 73, elected as Class I director effective February 20, 2025.","Kirsch brings experience as Senior Advisor at Alvarez & Marsal Life Sciences Industry Group.","Annual cash retainer of $45,000 plus initial option to purchase 164,800 shares vesting over 36 months.","Kirsch currently serves on board of Liquidia Technologies (LQDA); previously on boards of Kadmon, Immunomedics, POZEN, Aralez.","Compensation follows Non-Employee Director Compensation Program disclosed in Q2 2024 Form 10-Q."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":376127383.4285714,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174876,"accession_number":"0001193125-25-005424","cik":1593899,"company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atea reports $454.7M cash, plans global Phase 3 HCV program starting Q1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents and marketable securities $454.7M at Dec 31, 2024; cash runway into 2028.","Phase 2 study met primary endpoints: 98% SVR12 in per-protocol population, 95% in efficacy evaluable (n=256).","Global Phase 3 program for bemnifosbuvir + ruzasvir expected to initiate in Q1 2025; two open-label trials.","End-of-Phase 2 meeting with FDA scheduled January 2025 to discuss Phase 3 program design.","Company estimates global HCV market ~$3B annual net sales; regimen has potential best-in-class profile."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":376127383.4285714,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191833,"accession_number":"0001193125-24-253143","cik":1593899,"company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atea Q3 net loss $31.2M (-$0.37/sh); COVID-19 Phase 3 fails, HCV topline Dec 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $31.2M ($0.37 diluted EPS) vs $33.1M loss ($0.40) YoY; cash $482.8M at Sept 30.","Phase 3 SUNRISE-3 COVID-19 trial missed primary endpoint; no regulatory path pursued.","Phase 2 HCV study (n=275) topline SVR12 results expected early Dec 2024; FDA End-of-Phase 2 meeting planned Q1 2025.","R&D spend $26.2M, down $2.0M YoY due to lower COVID spend offset by higher HCV costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":376127383.4285714,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208316,"accession_number":"0001193125-24-195895","cik":1593899,"company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atea reports Q2 net loss $40.5M; Phase 2 HCV data show 97% SVR12; Phase 3 COVID-19 trial due 2H24","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $40.5M for Q2 2024 (diluted EPS -$0.48) vs $28.2M loss in Q2 2023; cash balance $502.2M.","R&D expenses rose to $34.7M (+$12.6M YoY) driven by Phase 2/3 trial costs.","Full enrollment in global Phase 2 HCV study (bemnifosbuvir + ruzasvir); SVR12 results expected 4Q 2024.","Lead-in cohort (n=60) at EASL achieved 97% SVR12 with 8-week treatment; no drug-related serious AEs.","Phase 3 SUNRISE-3 (bemnifosbuvir for COVID-19) topline data anticipated in 2H 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":376127383.4285714,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225938,"accession_number":"0001193125-24-165886","cik":1593899,"company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Atea Pharmaceuticals re-elects two Class I directors; Berger receives 48% withhold votes","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Franklin Berger elected with 30.5M for, 28.3M withheld (48% withhold); Sommadossi elected with 40.8M for, 18.1M withheld.","KPMG LLP ratified as auditor for FY2024: 62.3M for, 6.5M against, 5.6M abstain.","Say-on-pay proposal approved on advisory basis: 42.9M for, 15.5M against, 0.4M abstain.","88.3% of outstanding shares voted (74.4M of 84.3M shares)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":376127383.4285714,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225937,"accession_number":"0001193125-24-138249","cik":1593899,"company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atea Q1 2024 net loss $63.2M; Phase 3 COVID trial enrollment complete, results due 2H 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $63.2M ($0.75 per share) vs $35.5M ($0.43) in Q1 2023.","R&D expense nearly doubled to $57.6M, driven by Phase 3 SUNRISE-3 and Phase 2 HCV trials.","Cash, equivalents, and marketable securities $541.5M, down $36.6M from year-end 2023.","Phase 3 COVID trial fully enrolled (2,221 patients in monotherapy cohort); topline results expected 2H 2024.","Phase 2 HCV lead-in cohort confirmed 98% SVR4; full Phase 2 results expected 2H 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":376127383.4285714,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245036,"accession_number":"0001193125-24-050724","cik":1593899,"company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atea reports $136M FY2023 net loss; HCV Phase 2 confirms 98% SVR4; COVID-19 Phase 3 enrollment >1,400","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $39.2M ($0.47 diluted EPS) vs $34.4M loss in Q4 2022; FY net loss $136.0M ($1.63) vs $115.9M.","Cash & marketable securities $578.1M at Dec 31, 2023, down from $646.7M at Dec 31, 2022.","HCV Phase 2 lead-in final results: 98% SVR4 (58/59 patients); enrollment reinitiated for up to 220 patients, including cirrhotics.","COVID-19 Phase 3 SUNRISE-3: >1,400 patients enrolled in monotherapy cohort; interim analyses expected March 2024 and Q2 2024.","Topline results for SUNRISE-3 and HCV Phase 2 SVR12 both anticipated in H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":376127383.4285714,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262480,"accession_number":"0001193125-23-273532","cik":1593899,"company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atea Pharma Q3 net loss widens to $33.1M; cash at $595.1M; pipeline milestones on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $33.1M ($0.40/share) vs $8.1M ($0.10) a year ago, driven by R&D spending surge to $28.2M.","Cash, cash equivalents and marketable securities $595.1M at Sept 30, down $13M from June 30.","Phase 3 SUNRISE-3 for bemnifosbuvir in COVID-19 enrollment ongoing; first interim analysis expected Q1 2024.","Phase 2 HCV combination trial (bemnifosbuvir + ruzasvir) lead-in cohort fully enrolled; initial data also due Q1 2024.","Interest income rose to $7.9M from $4.4M on higher yields; total operating expenses $40.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":376127383.4285714,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279663,"accession_number":"0001193125-23-206247","cik":1593899,"company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atea Pharma Q2 net loss $28.2M; progresses COVID-19 & HCV trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $28.2M in Q2 2023 (EPS -$0.34) compared to $31.3M loss in Q2 2022.","Cash, equivalents and marketable securities $608.1M, down $38.6M from Dec 2022.","Phase 3 SUNRISE-3 trial amended: eligibility broadened, target enrollment ~2,200; topline expected mid-2024.","Phase 2 HCV study of bemnifosbuvir+ruzavir dosing; initial data from lead-in cohort (~60 pts) expected 4Q23.","R&D expenses rose to $22.1M from $19.9M YoY, driven by trial costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":376127383.4285714,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298091,"accession_number":"0001193125-23-171257","cik":1593899,"company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","form_type":"8-K","filed_at":"2023-06-21T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Atea Pharmaceuticals amends bylaws and reports annual meeting voting results","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bylaws amended to adopt universal proxy rules and enhance stockholder nomination disclosure.","Directors Jerome Adams and Barbara Duncan elected with 34.5M and 40.6M votes for, respectively.","Advisory vote on executive compensation approved with 40M for (70% of votes cast).","Ratification of KPMG as auditor approved with 64.5M for, 6.3M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":376127383.4285714,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298090,"accession_number":"0001193125-23-138257","cik":1593899,"company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atea Q1 net loss $35.5M ($0.43/share); cash $620.5M; progresses bemnifosbuvir trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $35.5M ($0.43 diluted EPS) vs $42.1M ($0.51) in Q1 2022; no revenue.","Cash, cash equivalents & marketable securities $620.5M at March 31, 2023 vs $646.7M at Dec 31, 2022.","R&D expense $29.0M, G&A $12.6M; both roughly flat YoY; interest income rose to $6.3M.","FDA granted Fast Track designation for bemnifosbuvir in COVID-19; Phase 3 SUNRISE-3 enrolling.","Phase 2 HCV combination (bemnifosbuvir + ruzasvir) dosing expected 2Q23; initial data 4Q23; dengue program deprioritized."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":376127383.4285714,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318335,"accession_number":"0001193125-23-053843","cik":1593899,"company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atea reports Q4 2022 net loss of $34.4M; provides clinical updates on COVID-19, HCV, and dengue programs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $34.4M ($0.41 loss per share) in Q4 2022 vs net income of $117.1M in Q4 2021; full year 2022 net loss $115.9M.","Revenue $0 in Q4 and full year 2022 vs $192.2M and $351.4M in 2021 due to end of Roche collaboration.","Cash and marketable securities $646.7M at Dec 31, 2022, down from $764.4M at Dec 31, 2021.","Phase 3 SUNRISE-3 trial for bemnifosbuvir in COVID-19 continues enrollment; interim analysis expected 2H23.","Dengue program deprioritized; Phase 2 HCV combination trial to start enrollment in 2Q23 with initial results by 4Q23."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":376127383.4285714,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336606,"accession_number":"0001193125-22-279097","cik":1593899,"company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atea Pharma reports Q3 net loss $8.1M; cash $665M; SUNRISE-3 enrollment imminent","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $8.1M ($0.10 per share) vs net loss of $28.2M in Q3 2021.","Cash and marketable securities $665.0M at Sept 30, 2022, down from $764.4M at Dec 31, 2021.","R&D expenses fell to $4.9M from $43.0M, aided by a $14.5M credit from Roche cost share close-out.","SUNRISE-3 Phase 3 trial for bemnifosbuvir in high-risk COVID-19 patients expected to start enrollment before year-end 2022.","AT-752 human challenge study and DEFEND-2 first cohort completion expected around year-end; HCV trial submission also anticipated."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":376127383.4285714,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354011,"accession_number":"0001193125-22-214871","cik":1593899,"company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","form_type":"8-K","filed_at":"2022-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atea Pharma Q2 net loss $31.3M; bemnifosbuvir enters late-stage COVID-19 trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $31.3M ($0.38 diluted loss per share) vs net income of $1.5M in Q2 2021; no collaboration revenue.","Cash and equivalents $684.5M at June 30, 2022, down from $764.4M at Dec 31, 2021.","Bemnifosbuvir to advance to global late-stage trial for COVID-19 in Q4 2022; primary endpoint hospitalization/death in high-risk patients.","MORNINGSKY Phase 3 missed primary symptom alleviation endpoint but showed 71% reduction in hospitalization (exploratory p=0.047).","AT-752 for dengue and HCV combo trial advancing; initial results expected Q4 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":376127383.4285714,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371858,"accession_number":"0001193125-22-177774","cik":1593899,"company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","form_type":"8-K","filed_at":"2022-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Atea Pharmaceuticals stockholders elect three Class II directors, approve 'one year' say-on-pay frequency","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Bruno Lucidi, Polly A. Murphy, and Bruce Polsky as Class II directors (over 55.7M votes each, no broker non-votes included).","Advisory vote on executive compensation frequency: ONE year approved with 59,857,505 votes for (99.4% of votes cast).","Ratification of KPMG LLP as independent auditor for 2022 passed with 71,630,493 votes for, 281,592 against, 35,490 abstain.","Approximately 86.41% of outstanding shares were represented at the meeting (71,947,575 shares of common stock)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":376127383.4285714,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371857,"accession_number":"0001193125-22-145634","cik":1593899,"company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atea Q1 net loss $42.1M; bemnifosbuvir misses primary endpoint but shows 71% hospitalization reduction","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $42.1M ($0.51 per diluted share) vs net income of $30.7M in Q1 2021; revenue $0 vs $65.985M due to Roche termination.","Cash and equivalents $705.5M at March 31, 2022, down from $764.4M at Dec 31, 2021; $25M paid to Merck for ruzasvir license.","Bemnifosbuvir MORNINGSKY trial: primary endpoint (time to symptom alleviation) not met; 71% reduction in hospitalization (2.9% vs 10%, p=0.047, exploratory).","Phase 2 hospitalized COVID-19 study: 7.5% PRI on bemnifosbuvir vs 10% placebo; 0 deaths vs 3 deaths in placebo.","Initiated Phase 2 DEFEND-2 and human challenge trial for AT-752 in dengue; results expected 4Q22 and late 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":376127383.4285714,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390773,"accession_number":"0001193125-22-057911","cik":1593899,"company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","form_type":"8-K","filed_at":"2022-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atea reports Q4 net income of $117.1M on Roche revenue recognition; pivots COVID-19 pipeline to combo","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2021 net income $121.2M vs net loss $10.9M in 2020; revenue of $351.4M from Roche license termination.","Phase 3 MORNINGSKY trial closed; COVID-19 program shifts to Phase 2 combination with a protease inhibitor in 2H 2022.","Initiated Phase 2 HCV combination trial of bemnifosbuvir and ruzasvir (in-licensed from Merck) in 2H 2022.","AT-752 Phase 2 dengue program expected to start 1H 2022 with results late 2022; cash $764.4M at Dec 31, 2021.","Roche collaboration terminated effective Feb 10, 2022; Atea regains full worldwide rights to bemnifosbuvir."],"consensus_eps_estimate":null,"consensus_eps_actual":1.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":351367000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":376127383.4285714,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390772,"accession_number":"0001193125-22-005119","cik":1593899,"company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Atea Pharmaceuticals posts slide presentation at J.P. Morgan Healthcare Conference","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company made a corporate slide deck available on its website for the J.P. Morgan Healthcare Conference.","The filing does not disclose specific financial or pipeline updates; the slide content is not reproduced in the 8-K.","Investors should consult the posted presentation directly for any material developments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":376127383.4285714,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":408878,"accession_number":"0001193125-21-341283","cik":1593899,"company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","form_type":"8-K","filed_at":"2021-11-26T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Atea cancels CEO's fireside chat at Evercore ISI HealthCONx Conference","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Nov 22, Atea announced CEO Jean-Pierre Sommadossi would participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on Dec 1, 2021.","On Nov 26, Atea determined it will not participate in that fireside chat; no webcast or recording will be available.","No reason for cancellation was provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":376127383.4285714,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":408877,"accession_number":"0001193125-21-331369","cik":1593899,"company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","form_type":"8-K","filed_at":"2021-11-16T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Roche terminates license agreement for AT-527 with Atea; effective Feb 10, 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Roche sent termination notice on Nov 12, 2021; license ends Feb 10, 2022.","Agreement covered ex-U.S. rights to develop and commercialize AT-527.","No early termination penalties will be incurred by Atea.","Atea retains full rights to AT-527 outside the terminated pact."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":376127383.4285714,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":408876,"accession_number":"0001193125-21-327268","cik":1593899,"company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","form_type":"8-K","filed_at":"2021-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atea reports Q3 net loss $28.2M; plans Phase 3 MORNINGSKY amendment with new primary endpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $28.2M for Q3 2021 vs $17.6M loss in Q3 2020; collaboration revenue $32.8M from Roche license.","Cash and equivalents $839.7M as of Sept 30, 2021, down from $850.1M at Dec 31, 2020.","Phase 3 MORNINGSKY amendment: primary endpoint to hospitalization/death; focus on unvaccinated high-risk; dose increased to 1,100 mg BID; data H2 2022.","New infectious virus data from Phase 2 MOONSONG show rapid viral load reduction (-0.5 log10) with AT-527 1,100 mg BID vs placebo at Day 3 in overall population.","In vitro data show AT-511 (free base of AT-527) maintains potency against variants including Delta."],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":159187000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":376127383.4285714,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}